Review of Molecular Technologies for Investigating Canine Cancer.

Simple Summary: Genetic molecular testing is starting to become part of standard clinical practice for dogs with cancer as it can assist veterinarians with diagnosis, provide information about prognosis and aid with selection of therapeutic options. In this review, we consider the different body fluids and tissues from which tumour cells, DNA, RNA and the relevant proteins can be isolated, and what methods are currently used for characterising the molecular profile of cancer in dogs. We also consider new methods that are currently being developed and look promising. The aim is to provide an overview of molecular technologies for veterinarians without previous experience in molecular biology. Genetic molecular testing is starting to gain traction as part of standard clinical practice for dogs with cancer due to its multi-faceted benefits, such as potentially being able to provide diagnostic, prognostic and/or therapeutic information. However, the benefits and ultimate success of genomic analysis in the clinical setting are reliant on the robustness of the tools used to generate the results, which continually expand as new technologies are developed. To this end, we review the different materials from which tumour cells, DNA, RNA and the relevant proteins can be isolated and what methods are available for interrogating their molecular profile, including analysis of the genetic alterations (both somatic and germline), transcriptional changes and epigenetic modifications (including DNA methylation/acetylation and microRNAs). We also look to the future and the tools that are currently being developed, such as using artificial intelligence (AI) to identify genetic mutations from histomorphological criteria. In summary, we find that the molecular genetic characterisation of canine neoplasms has made a promising start. As we understand more of the genetics underlying these tumours and more targeted therapies become available, it will no doubt become a mainstay in the delivery of precision veterinary care to dogs with cancer. [ABSTRACT FROM AUTHOR]